Article

의사-제약산업체 상호작용에서의 이해상충 관리

강명신1, 고윤석2,*
Myoung Sheen KANG1, Younsuck KOH2,*
Author Information & Copyright
1연세대학교 보건대학원 보건정책관리학과 보건의료법윤리전공
2울산대학교 의과대학 서울아산병원 인문사회의학교실 및 호흡기내과
1Department of Health Policy and Management, Division of Public Health Law and Ethics, Graduate School of Public Health, Yonsei University
2Department of Medical Humanities & Social Sciences, Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine
*교신저자: 고윤석. 울산대학교 의과대학 서울아산병원 인문사회의학교실 및 호흡기내과. 02-3010-3134. yskoh@amc.seoul.kr

ⓒ Copyright 2011 The Korean Society for Medical Ethics. This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: Aug 27, 2011; Accepted: Sep 16, 2011

Published Online: Sep 30, 2011

ABSTRACT

Physician-pharmaceutical industry interaction (PPII) is ubiquitous in medical research, education, and clinical care. Conflicts of interest, which occur in the interaction, are to be properly managed at the level of the health care institution as well as at the level of individual health care personnel. The purpose of that management is to control conflicts of interest to the maximum extent possible, thereby preserving the value of public trust. Public trust is founded on the principle of prioritizing patients’ interests. Founding principles of COI management are based on public trust, professional integrity, and publicity. With these founding principles the relevant stakeholders (the pharmaceutical industry, physicians, medical care institutions, and the general public) should make continuous efforts to manage COI appropriately. Above all, the awareness of influences is essential among those stakeholders. This article argues that medical professionals should appreciate and protect the value of professional integrity and that medical organizations and institutions should establish reasonable policies of COI management, including the constitution of COICs (conflicts of interest committees) and education programs. Furthermore, it is claimed that society as a whole shares the responsibility of providing an appropriate health care environment by compensating heath care providers with adequate payment in order to avoid inappropriate PPII development. Without providing reasonable health care reimbursement, legal restrictions designed to control inappropriate PPII maAy not achieve their goal.

Keywords: 이해상충; 의사-제약회사 상호작용; 공적 신뢰; 온전성; 공지성
Keywords: conflicts of interest (COI); physician-pharmaceutical industry interaction (PPII); public trust; professional integrity; publicity


[2024년 12월 특집 논문] 헬스케어 AI 윤리에서 환자·시민 참여 모형: 주제범위고찰과 방법론적 검토에 기초하여


2024년 12월 호(12월 31일 발행)에서는 특집호를 계획하고 있으며, 특집논문에 대한 논평을 받고 있습니다.

 - 특집논문에 대한 논평을 작성하시고자 하는 선생님께서는 논평자의 학문적 지견과 관점을 담아 특집논문을 논평해 주시기 바랍니다.

 - 특집논문의 전체 본문은 첨부파일로 올라와 있습니다.

 - 논평 작성을 위해서 교정 및 편집 전 파일로 업로드되어 있으며, 작업이 완료되는대로 파일은 교체할 예정입니다.

공지사항 바로가기


I don't want to open this window for a day.